

Omalizumab (Xolair) for Allergy-Induced Asthma

🕒 Expires Thursday, October 31, 2019

📖 Nursing

👤 Colleen Symanski-Sanders, RN

Examination

1. Though exact numbers regarding the incidence of asthma do not exist because of differences in location and a lack of a uniform diagnosis, it has been suggested that approximately _____ of adults have some form of the disease.
 - a. 1% to 3%
 - b. 4% to 5%
 - c. 5% to 7%
 - d. 7% to 10%
 - e. 10% to 13%
2. Xolair's benefit to patients, once it reaches a therapeutic level, is a
 - a. decrease in the number of allergy-induced asthma attacks
 - b. smaller dose of a patient's normal medication is required to treat acute episodes
 - c. lessening of the symptoms when an allergy-induced asthma attack occurs
 - d. decrease in the incidence of all types of asthma attacks
 - e. better tolerance of drugs such as aspirin
3. When allergens enter the body, the body responds by producing ____ antibodies.
 - a. IgM
 - b. IgE
 - c. IgG
 - d. IgA
 - e. mast cell
4. IgE circulating in the blood attaches to _____ cells and triggers the release of inflammatory chemicals such as histamine and leukotrienes.
 - a. histamine
 - b. alveolar
 - c. stem
 - d. mast
 - e. leukotriene
5. Organs that contain mast cells include all of the following EXCEPT
 - a. eyes
 - b. nose
 - c. skin
 - d. respiratory tract
 - e. urinary tract
6. Xolair binds to the
 - a. mast cells in the blood and blocks the release of inflammatory substances
 - b. alveolar cells in the respiratory tract and blocks the action of IgE antibody
 - c. circulating IgE antibodies in the blood, decreasing the amount that are available
 - d. histamine receptors, which inhibits the response that normally would occur
 - e. leukotriene cells in the respiratory tract and blocks the release of inflammatory substances

7. In the clinical trials that occurred on Xolair, the maximum Xolair dose that patients received, who were included in the study, was
- 150 mg per week
 - 750 mg per two weeks
 - 150 mg per four weeks
 - 375 mg per four weeks
 - 750 mg per four weeks
8. Regarding pregnancy and lactation, all of the following statements are true EXCEPT
- Studies have confirmed that Xolair is present in human milk.
 - Xolair should only be used during pregnancy if clearly needed and used cautiously by nursing mothers.
 - There were no well-controlled studies of Xolair use by pregnant women.
 - Researchers have concluded that it is reasonable to expect the presence of Xolair in human milk as well.
 - Reproduction studies in animals are not always able to predict human reproduction outcomes.
9. The dosages and dosing frequency for Xolair are determined by
- the total serum IgE level in IU/mL (measured before the start of treatment), as long as the body weight does not exceed 150 pounds
 - the total serum IgE level in IU/mL (measured at the end of treatment) only
 - the total serum IgE level in IU/mL (measured at the end of treatment) and body weight in kilograms
 - the total serum IgE level in IU/mL (measured before the start of treatment) and body weight in kilograms
 - body weight only
10. Regarding the Xolair injection, there is a limit of _____ per injection site.
- 75 mg
 - 100 mg
 - 150 mg
 - 375 mg
 - 750 mg
11. The injection of Xolair can take up to _____ because of its viscosity.
- 5 seconds
 - 10 seconds
 - 15 seconds
 - 30 seconds
 - 1 minute
12. Regarding the administration of Xolair, all of the following statements are true EXCEPT
- A fully reconstituted product may have a few small bubbles or foam around the edge of the vial
 - The reconstituted product is viscous
 - A fully reconstituted product appears clear or slightly opalescent
 - The lyophilized product takes 15-20 seconds to dissolve
 - Xolair is injected subcutaneously, not intramuscularly
13. Regarding the injection technique, once the liquid is mixed with the Xolair powder, all of the following statements are true EXCEPT
- Some vials may take longer than 20 minutes to dissolve completely
 - There should be no visible gel-like particles in the solution
 - Do not use if foreign particles are present
 - It is acceptable to have small bubbles or foam around the edge of the vial.
 - gently shake the vial for 5-10 seconds approximately every 5 minutes in order to dissolve any remaining solids
14. Do not use if the contents of a vial of Xolair if it does not dissolve completely by

- a. 15 seconds
- b. 5 minutes
- c. 20 minutes
- d. 40 minutes
- e. 1 hour

15. **The most serious adverse reactions that were reported during the Xolair clinical trials were**

- a. skin reactions and pharyngitis
- b. malignancies and anaphylaxis
- c. viral infections and sinusitis
- d. sinusitis and pharyngitis
- e. upper respiratory tract infections and skin reactions

16. **All of the following statements regarding injection site reactions are true EXCEPT**

- a. Most of the site reactions lasted less than 8 days.
- b. The findings suggest that a skin reaction may be the result of a reaction to the drug itself, rather than injecting a viscous liquid subcutaneously.
- c. Reactions tended to decrease in frequency after subsequent injections.
- d. The incidence of reactions in the Xolair-treated patients compared with the placebo-treated patients was not significantly different.
- e. Most of the site reactions happened within one hour post injection.

17. **Regarding the risk of malignancy with Xolair use, all of the following statements are true EXCEPT**

- a. The risk of developing malignant neoplasms compared to controls did not reach statistical significance but did show a trend.
- b. The majority of patients were observed for less than 1 year.
- c. The impact of longer exposure to Xolair is of more concern, because this will most likely increase the risk of developing a malignancy.
- d. The impact of use in patients at higher risk for malignancy (i.e. the elderly or smokers) is currently not known.
- e. The issue of whether or not there is a higher risk for malignancy if the drug is used will require further investigation.

18. **Anaphylaxis can occur following the administration of any medication. For Xolair, it is recommended that a _____ reaction window be observed.**

- a. two hour
- b. six hour
- c. one hour
- d. 30 minute
- e. twelve hour

19. **Regarding patient education, all of the following statements are true EXCEPT**

- a. is meant for the treatment of acute bronchospasm or status asthmaticus
- b. do not inject within two inches of your naval, near scars or bruises, or close to the groin or joint areas
- c. inject at least 1 1/2 inches away from the last injection site
- d. an effect may take up to 12 weeks
- e. the injection site must be an area with a subcutaneous layer, such as the top of the thighs or the buttocks

20. **Xolair should be kept refrigerated at**

- a. 0 degrees F to 15 degrees F
- b. 50 degrees F to 65 degrees F
- c. 15 degrees F to 32 degrees F
- d. 60 degrees F to 75 degrees F
- e. 36 degrees F to 46 degrees F



©2018 All Rights Reserved, e-EdCredits.com